The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 21, 2022
Filed:
Feb. 18, 2020
Applicant:
Cellectis, Paris, FR;
Inventors:
Assignee:
CELLECTIS, Paris, FR;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C12N 15/85 (2006.01); C12N 5/0783 (2010.01); C12N 9/22 (2006.01); C12N 15/90 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C12N 15/85 (2013.01); A61K 35/17 (2013.01); C12N 5/0636 (2013.01); C12N 5/0637 (2013.01); C12N 5/0638 (2013.01); C12N 9/22 (2013.01); C12N 15/90 (2013.01); C12N 15/1138 (2013.01); C12N 2310/20 (2017.05); C12N 2510/00 (2013.01); C12Y 301/00 (2013.01);
Abstract
The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.